This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with non–small cell lung cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.